Zoetis Inc. (NYSE:ZTS) posted its quarterly earnings results on Tuesday. The company reported $0.53 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.53, MarketWatch Earnings reports. The firm had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.27 billion. Zoetis had a net margin of 17.25% and a return on equity of 65.35%. Zoetis’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.49 earnings per share.

Zoetis (NYSE ZTS) opened at 61.83 on Tuesday. The firm’s 50-day moving average is $62.59 and its 200 day moving average is $57.66. Zoetis has a 12-month low of $46.86 and a 12-month high of $63.85. The stock has a market capitalization of $30.35 billion, a P/E ratio of 35.95 and a beta of 1.02.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Thursday, June 15th will be issued a dividend of $0.105 per share. The ex-dividend date of this dividend is Tuesday, June 13th. This represents a $0.42 annualized dividend and a yield of 0.68%. Zoetis’s dividend payout ratio (DPR) is currently 24.42%.

Several research firms have weighed in on ZTS. Zacks Investment Research lowered shares of Zoetis from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. Hilliard Lyons began coverage on shares of Zoetis in a report on Tuesday, June 20th. They issued a “buy” rating and a $77.00 target price on the stock. Argus reiterated a “buy” rating and issued a $69.00 target price (up from $60.00) on shares of Zoetis in a report on Tuesday, May 30th. Deutsche Bank AG restated a “buy” rating and issued a $65.00 price objective (up from $62.00) on shares of Zoetis in a report on Monday, July 17th. Finally, CL King initiated coverage on shares of Zoetis in a report on Friday, May 26th. They issued a “buy” rating and a $71.00 price objective on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $64.78.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/08/08/zoetis-inc-zts-announces-earnings-results-hits-estimates.html.

In other Zoetis news, insider Catherine A. Knupp sold 5,785 shares of the company’s stock in a transaction dated Friday, May 12th. The shares were sold at an average price of $60.16, for a total value of $348,025.60. Following the completion of the sale, the insider now directly owns 24,415 shares of the company’s stock, valued at approximately $1,468,806.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.31% of the stock is currently owned by corporate insiders.

Large investors have recently modified their holdings of the stock. Assetmark Inc. increased its stake in shares of Zoetis by 4.6% in the first quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock worth $102,000 after buying an additional 85 shares during the last quarter. Guardian Life Insurance Co. of America increased its stake in shares of Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock worth $102,000 after buying an additional 13 shares during the last quarter. Point72 Asia Hong Kong Ltd acquired a new stake in shares of Zoetis during the first quarter worth $111,000. Advisory Services Network LLC acquired a new stake in shares of Zoetis during the first quarter worth $112,000. Finally, First Interstate Bank increased its stake in shares of Zoetis by 3.5% in the first quarter. First Interstate Bank now owns 2,250 shares of the company’s stock worth $120,000 after buying an additional 76 shares during the last quarter. 94.51% of the stock is owned by institutional investors.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Earnings History for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.